Burning Rock Biotech Limited (BNR) Bundle
A Brief History of Burning Rock Biotech Limited (BNR)
Founding and Early Development
Founding and Early Development
Burning Rock Biotech Limited was founded in 2014 in Guangzhou, China, by Mr. Yusen Zhang and a team of scientists. The company's mission is to provide advanced genomic solutions in the field of precision medicine.
Initial Public Offering (IPO)
Burning Rock went public on the Nasdaq stock exchange on July 31, 2020. The IPO price was set at $16 per American Depositary Share (ADS), raising approximately $85 million.
Financial Performance (2020-2023)
| Year | Revenue (in million $) | Net Income (in million $) | Total Assets (in million $) | Market Capitalization (in million $) |
|---|---|---|---|---|
| 2020 | 30.2 | -17.4 | 100.5 | 450 |
| 2021 | 40.5 | -12.3 | 120.8 | 600 |
| 2022 | 52.7 | -5.6 | 152.3 | 830 |
| 2023 (Projected) | 75.0 | 0.5 | 180.0 | 1,000 |
Product Offerings
Burning Rock specializes in comprehensive genomic testing and has developed products such as:
- Liquid biopsy tests for cancer detection
- Genetic screening for hereditary diseases
- Pharmacogenomics services
Strategic Partnerships
The company has established partnerships with numerous institutions and organizations, including:
- China Medical University Hospital
- Peking University
- Memorial Sloan Kettering Cancer Center
Regulatory Approvals
Burning Rock has received various regulatory approvals, including:
- FDA Breakthrough Device Designation for certain liquid biopsy tests
- CE Mark certification for its genomic testing products in Europe
Research and Development
The company has invested heavily in R&D, amounting to over $20 million in 2022. This investment focuses on enhancing its diagnostic capabilities and expanding its product line.
Recent Financial Trends
In 2023, Burning Rock reported a significant improvement in financial performance:
- Gross Margin: 45%
- Operating Margin: 3%
Market Position
Burning Rock is recognized as one of the leading players in the genomic diagnostics sector in China, with a market share of approximately 20% as of 2023.
Stock Performance
As of October 2023, the stock price of Burning Rock traded at approximately $15.40 per ADS, reflecting a market capitalization close to $950 million.
Future Projections
Looking ahead, analysts project that Burning Rock will continue growing, with estimated revenues reaching $100 million by 2024, driven by increased demand for genomic testing services.
A Who Owns Burning Rock Biotech Limited (BNR)
Shareholding Structure
As of the latest filing in 2023, the ownership of Burning Rock Biotech Limited (BNR) is distributed among various institutional and individual shareholders. The following table illustrates the primary stakeholders:
| Shareholder | Ownership Percentage | Number of Shares | Type of Ownership |
|---|---|---|---|
| Forward Ventures | 15.2% | 8,640,000 | Institutional Investor |
| Wellington Management Company | 9.8% | 5,520,000 | Institutional Investor |
| Fidelity Investments | 7.5% | 4,200,000 | Institutional Investor |
| Hong Kong Shanghai Alliance Holdings Limited | 5.1% | 2,850,000 | Individual Investor |
| Other Shareholders | 62.4% | 34,990,000 | Various |
Top Executives
The executive team at Burning Rock Biotech plays a significant role in the company's operations and strategy. Below are the key executives and their ownership interests:
| Name | Position | Ownership Percentage | Number of Shares |
|---|---|---|---|
| Yuan Gao | CEO | 1.9% | 1,060,000 |
| Xiaoyun Zhang | CFO | 0.7% | 385,000 |
| Yanjun Li | CTO | 0.5% | 275,000 |
| Feng Li | COO | 0.3% | 165,000 |
Market Capitalization
As of October 2023, Burning Rock Biotech has a market capitalization of $560 million. The stock trades on the NASDAQ under the ticker symbol BNR.
Recent Financial Performance
Burning Rock Biotech reported the following financial results for the fiscal year 2022:
| Financial Metric | Amount (in USD) |
|---|---|
| Total Revenue | $45 million |
| Net Loss | ($20 million) |
| Cash and Cash Equivalents | $100 million |
| Total Assets | $200 million |
Institutional Ownership Trends
Over the past year, the trend observed in institutional ownership has shown fluctuations. The percentage of shares held by institutional investors stood at 33% in Q1 2023, having increased from 29% in Q4 2022.
Recent Developments in Shareholder Structure
In 2023, the recent acquisition spree has led to significant changes in the shareholder structure:
- Forward Ventures increased its stake by 3%.
- Wellington Management introduced new shares, boosting its holding.
- Fidelity reduced its position by 1.5%.
Conclusion on Ownership Dynamics
The ownership dynamics at Burning Rock Biotech Limited reflect a blend of institutional and individual shareholders, alongside a well-established executive team. These factors play a crucial role in shaping the company's future direction and overall governance.
Burning Rock Biotech Limited (BNR) Mission Statement
Core Mission
The mission of Burning Rock Biotech Limited is to leverage cutting-edge technologies to provide comprehensive genomic solutions for cancer patient management. The company strives to improve the diagnostic accuracy and treatment outcomes through innovative and reliable liquid biopsy technologies.
Vision and Values
- Innovation: Commitment to advancing genomic technologies.
- Integrity: Upholding the highest standards of quality and ethics.
- Collaboration: Partnering with healthcare professionals and institutions.
- Patient-Centric: Focus on improving patient experiences and outcomes.
Recent Financial Performance
As of Q2 2023, Burning Rock Biotech reported revenues of approximately $25 million, marking a 30% year-over-year increase. The net loss for the same period was reported at $12 million.
Strategic Goals
- Market Expansion: Targeting growth in the global oncology market, expected to reach $250 billion by 2027.
- R&D Investment: Allocating at least 25% of revenue to research and development annually.
- Partnership Development: Establishing 5 new collaborations with pharmaceutical companies by the end of 2024.
Key Products and Services
| Product/Service | Description | Market Segment | Revenue Contribution (2022) |
|---|---|---|---|
| Liquid Biopsy | Non-invasive blood test for cancer diagnostics | Oncology | $15 million |
| Genomic Sequencing | Comprehensive genomic profiling for personalized treatment | Precision Medicine | $10 million |
| Clinical Trials | Diagnostic services for clinical trial participants | Biopharma | $5 million |
Commitment to Research
Burning Rock allocates approximately $6 million per year to clinical research initiatives, with over 30 ongoing clinical trials aimed at evaluating the effectiveness of its assays.
Global Presence
Burning Rock operates in multiple countries, including:
- United States
- China
- Germany
- Japan
The international revenue contributed to 40% of the total revenue in 2022.
Regulatory Approvals
As of October 2023, Burning Rock has received regulatory approvals, including:
- FDA Approval for its liquid biopsy tests in the U.S.
- CE Mark for its genomic assays in the European Union.
Future Outlook
Looking ahead, Burning Rock anticipates an annual growth rate of 25% through 2025, driven by innovation and expanding market reach.
How Burning Rock Biotech Limited (BNR) Works
Company Overview
Company Overview
Burning Rock Biotech Limited (BNR) is a biotechnology company based in China, focusing on precision oncology. It specializes in providing genomic profiling solutions for early cancer detection and monitoring. As of the end of 2022, the company reported a revenue of approximately $35 million, marking a year-over-year growth of around 15%.
Business Model
The company's business model involves the development and commercialization of next-generation sequencing (NGS) tests for cancer detection. They utilize proprietary technology to analyze gene mutations, which aids in personalized treatment plans for patients.
Product Offerings
Burning Rock Biotech offers a range of products and services, including:
- Genomic testing for lung cancer
- Comprehensive genomic profiling assays
- Liquid biopsy tests
- Clinical decision support tools
Financial Performance
As of Q3 2023, Burning Rock Biotech reported:
| Quarter | Revenue (in million $) | Net Income (in million $) | Operating Expenses (in million $) |
|---|---|---|---|
| Q1 2023 | 10 | -2 | 8 |
| Q2 2023 | 12 | -1 | 7 |
| Q3 2023 | 13 | -1.5 | 6 |
Market Position
Burning Rock Biotech holds a significant position in the oncology testing market in China, with an estimated market share of 12% as of early 2023. The global liquid biopsy market is expected to reach $6.5 billion by 2027, providing substantial growth opportunities for the company.
Partnerships and Collaborations
The company has established collaborations with various institutions and healthcare providers. For instance, in 2023, Burning Rock partnered with the Chinese Academy of Medical Sciences to enhance cancer research initiatives.
Regulatory Approvals
Burning Rock Biotech has received several regulatory approvals for its products, including:
- CE Mark for NGS products in Europe
- CFDA approvals for liquid biopsy tests
- CLIA certification for clinical laboratories in the USA
R&D Investments
In 2022, the company allocated approximately $14 million to research and development, focusing on expanding its product portfolio and enhancing testing capabilities. The R&D investment represents 40% of total revenues.
Future Outlook
Analysts predict that Burning Rock Biotech's revenue will grow at a CAGR of 20% over the next five years, primarily driven by increasing demand for precision medicine and advancements in genomic technologies.
How Burning Rock Biotech Limited (BNR) Makes Money
Core Business Model
Core Business Model
Burning Rock Biotech Limited (BNR) primarily generates revenue through its molecular diagnostic services. The company focuses on providing solutions for precision oncology utilizing next-generation sequencing (NGS) technology.
Revenue Streams
- Clinical Testing Services: BNR offers a variety of genomic testing services for cancer patients, including liquid biopsy tests.
- Pharmaceutical Collaborations: Revenue from partnerships with pharmaceutical companies for biomarker testing and clinical trial support.
- Research and Development Services: Income from providing R&D services to research institutions and biotech companies.
- Product Sales: Sales of proprietary diagnostic products and related reagents.
Financial Performance
As of Q3 2023, Burning Rock reported total revenues of RMB 204.5 million. This marked a 25% increase compared to RMB 163.3 million in the same quarter of the previous year.
Revenue Breakdown
| Revenue Source | Q3 2023 Revenue (RMB million) | Q3 2022 Revenue (RMB million) | Year-over-Year Growth (%) |
|---|---|---|---|
| Clinical Testing Services | 150.0 | 120.0 | 25.0 |
| Pharmaceutical Collaborations | 30.0 | 25.0 | 20.0 |
| Research and Development Services | 10.0 | 8.0 | 25.0 |
| Product Sales | 14.5 | 10.3 | 40.0 |
Cost Structure
Burning Rock's operating expenses include costs for research and development, as well as general and administrative expenses. As of the latest financial report, total operating expenses were RMB 190.0 million, leading to a net loss for Q3 2023 of RMB 30.0 million.
Growth and Expansion Plans
Burning Rock plans to expand its service offerings and enter new markets. It aims to increase its testing volumes to reach 1 million tests by 2025 and enhance its platform capabilities through continuous R&D investments.
Market Outlook
The global liquid biopsy market is expected to grow from USD 3.58 billion in 2021 to USD 11.65 billion by 2028, with a CAGR of 18.1%. BNR's positioning in this expansive market will be crucial for future revenue generation.
Key Partnerships
Burning Rock has established collaborations with notable pharmaceutical companies, including:
- Merck & Co.
- Amgen
- Novartis
Recent Developments
In August 2023, Burning Rock announced a strategic partnership with a leading biotech firm for joint development of NGS-based tests, potentially increasing its revenue from collaborative projects.
Summary of Financial Health
| Financial Metric | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|
| Total Revenue | RMB 204.5 million | RMB 180.0 million | RMB 150.0 million |
| Net Income (Loss) | (RMB 30.0 million) | (RMB 25.0 million) | (RMB 20.0 million) |
| Operating Expenses | RMB 190.0 million | RMB 175.0 million | RMB 150.0 million |
Burning Rock Biotech Limited (BNR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support